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Introduction
Metastasectomy is the most frequent surgical resection 
undertaken by thoracic surgeons (1). Lung is the second 
common site of metastases (1) and the role of pulmonary 
metastasectomy has been widely investigated by the 1970s (2) 
culminating in an important landmark publication in 1997 
reporting the results from the International Registry of 
Lung Metastasectomy (3,4).
From 2000 through 2011 the performance of all types 
of metastasectomy—irrespective of the anatomic target 
site (liver, lung, brain and adrenal glands)—increased 
substantially across common cancer types, notwithstanding 
various advances in systemic therapies; metastasectomy was 
performed more safely, despite increasing patient comorbidities 
and lung metastasectomies increased significantly, following 
liver metastasectomies that demonstrated the highest rate of 
increase of any metastatic site (5).
Colorectal neoplasms are the commonest epithelial lesions 
for which pulmonary metastasectomy is indicated (1) and 
they are the only type of primary cancer metastatic to the 
lungs for which a randomized trial is ongoing, comparing 
active monitoring versus active monitoring with pulmonary 
metastasectomy (6).
All the other types of primary cancers metastatic 
to the lungs (germ cell tumors, melanoma, sarcoma, 
gyneacological, urological, upper gastrointestinal as well 
as thyroid and kidney cancers) have been studied only by 
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non-randomized studies and the evidence for pulmonary 
metastasectomy still remains unproven (1).
Oncologic principles and surgical aspects
The present  oncologica l  cr i ter ia  for  pulmonary 
metastasectomy are: (I) the primary cancer need to be 
controlled or controllable (II) no extrathoracic metastasis—
that is not controlled or controllable—exists (III) all of the 
tumor must be resectable, with adequate pulmonary reserve 
(IV) there are no alternative medical treatment options with 
lower morbidity (7). 
Patients with favourable prognostic factors can 
survive longer irrespective of treatments while favorable 
predictive factors are those allowing to discriminate 
patients benefitting from particular treatments (8); general 
favourable prognostic features in patients with pulmonary 
metastases are: (I) one or few metastases; (II) long disease 
free interval; (III) normal CEA levels in colorectal cancers. 
Negative predictive features in patients candidate to 
pulmonary metastasectomies are: (I) active primary cancer; 
(II) extrathoracic metastases; (III) inability to obtain surgical 
radicality; (IV) mediastinal lymphatic spread (1).
It is estimated that 75% or more of patients with 
pulmonary nodules will also have metastases to extrathoracic 
sites; only 15% to 25% of patients have lesions confined 
to the lung and are appropriate candidates for curative 
resection (7). For this reason, staging for metastatic disease 
outside of the lung is performed prior to pulmonary 
resection, by CT of the chest and abdomen and, in selected 
cases, by PET scan and brain imaging with either MRI or 
CT scan (9).
Intrathoracic lymph node involvement is associated with 
decreased survival after pulmonary metastasectomy; the data 
are most convincing for colorectal and renal cell cancers 
and there is limited evidence as to whether mediastinal 
lymphadenectomy leads to improved survival in patients 
receiving lung metastasectomy (10-12).
Lung function testing is an important component 
to the preoperative evaluation of patients undergoing 
metastasectomy: although sublobar resections are most 
often used, cumulative parenchymal loss must be considered 
in the setting of multiple lesions (7,13); moreover, although 
“parenchyma-sparing” procedures still remain the gold 
standard, major pulmonary resections for treating lung 
metastases—including pneumonectomy or pulmonary 
resection with en bloc resection of the chest wall or other 
major structures (diaphragm, pericardium, superior vena 
cava)—have been reported with low mortality and morbidity 
rates and an acceptable long-term survival, when performed 
in selected patients susceptible to complete resection (14).
Patients with a predicted postoperative FEV 1 or DLCO 
between 30% and 60% predicted should have additional 
risk stratification with an exercise test, such as shuttle walk 
test or stair climb, prior to proceeding with surgery; patients 
with postoperative predicted FEV 1 or DLCO less than 30% 
should undergo formal cardiopulmonary exercise testing with 
measurement of maximal oxygen consumption (15).
Both video-assisted thoracic surgical (VATS) techniques 
and open thoracotomy are accepted as appropriate incisions 
for performing pulmonary metastasectomy (16); on one 
side, open techniques have been shown to lead to the 
detection and hence, resection of more metastases than 
VATS techniques, in particular in case of nodule deeply 
embedded within the parenchyma (16-18). On the contrary 
VATS has been considered a preferable approach due to 
superior functional outcome, offering a shorter hospital 
stay, a shorter duration of chest tube drainage and epidural 
analgesia (19) (Figures 1,2). 
Colorectal cancers
A quarter of patients with colorectal cancer have metastatic 
lesions at diagnosis and in nearly half of them, metastases will 
develop, often in liver or lung or both (20). Surgery has been 
consistently reported as a potentially curative option for 
liver-limited disease , with 5-year survival of 30–40% (21); 
in 10–15% of cases lung metastases are documented at 
advanced disease and are diagnosed mostly as multiple or 
bilateral metastases, with only 2% to 7% a single lesion (22).
The pract ice  of  pulmonary metastasectomy i s 
widespread, having a consensus regarding the effectiveness 
of the procedure with 5-year survival rates approximately 
30–50% (23); however, despite its widespread use, no 
results from prospective controlled or randomized trials are 
now available to confirm the evidence-based benefit of lung 
surgery (20).
Recently the GLIDA trial disclosed that early diagnosis 
of neoplasm recurrence is not related to overall survival 
implementation (24).
As reported before, the PulMiCC trial—comparing 
active monitoring versus active monitoring with pulmonary 
metastasectomy in patients suffering from pulmonary 
metastases from colorectal neoplasms—is ongoing and it 
will be probable able to provide evidence with respect to 
pulmonary metastasectomy in colorectal cancer (6,25).
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A recent study disclosed that major anatomic resection 
with lymphadenectomy for pulmonary metastasectomy 
can be considered in selected patient with sufficient 
functional reserve to improve the disease specific survival 
and disease free survival (26); nowadays is commonly 
stated that radicality of surgery is the major prognostic 
indicator of  long-term survival ,  whereas number 
and distribution of lung metastases, primary stage at 
diagnosis, elevated prethoracotomy carcinoembryonic 
antigen levels, disease-free interval, mediastinal or 
hilar lymphnode involvement, presence of solitary 
liver localization and systemic therapy are otherwise 
considered in retrospective studies (20).
Urinary tract cancers
After the initial report, there have been anecdotal reports 
that suggested the potential benefit of metastasectomy 
on survival of patients with urinary tract cancer (26,27). 
However, due to the rarity of oligometastases associated 
with advanced urinary tract carcinoma, little is known about 
the efficacy of metastasectomy and prognostic factors (27).
Despite a favorable initial response rate to chemotherapy 
(44–64%), long-term overall survival is achieved by only 
a minority of patients with metastatic urinary tract cancer 
and the median overall survival for this disease typically 
plateaus at approximately 14 to 15 months (28). In studies 
investigating the contribution of lung metastasectomy in 
patients with metastatic urinary tract cancer, overall survival 
was 30 months, longer when compared with that of patients 
who received mainly systemic chemotherapy (27).
For patients with isolated pulmonary metastases, 
metastasectomy for single lung metastasis is statistically 
related to longer time to progression than for patients 
receiving multiple lung metastasectomies but a longer 
time to progression does not translate into a longer overall 
survival (27). 
The present recommended strategy for consolidative 
surgery for metastatic tract cancer suggests to offer this 
treatment to patients who: (I) have responded to previous 
chemotherapy; (II) have disease recurrence at the initial 
or sole metastatic site; (III) have a tumor that is surgically 
resectable with clear margins; (IV) have a documented 
period of disease stability without evidence of rapid disease 
progression (29).
In case of renal cell carcinoma, patients receiving lung 
metastasectomy disclosed a significant survival advantage, 
mainly in case of isolated pulmonary metastases, although 
a survival advantage was observed even in patients with 
extrathoracic synchronous metastases receiving pulmonary 
resection (30); it is not clear if patients should receive lung 
metastasectomy when radical macroscopic radicality could 
not be achieved (30).
Osteosarcoma and soft tissue sarcomas
Sarcoma comprises a heterogeneous group of histologic 
subtypes with a propensity to metastasize to the lungs. 
Isolated pulmonary metastases occur in as many as 20% of 
patients diagnosed with soft tissue sarcoma and as many as 
Figure 1 Multiple, bilateral lung metastases not amenable of 
radical resection because of number, location and dimensions of 
the lesions.
Figure 2 Single metastasis of the right lower lobe amenable of 
radical resection.
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40% in those with a primary bone sarcoma (31).
Osteosarcoma is the most common primary cancer in 
young patients (32); three-fourths of patients metastases 
at diagnosis and about 30–40% of patients—without 
metastatic disease at diagnosis—develop subsequently lung 
metastases (33). 
Lung metastasectomy provides prolonged survival and 
should always be considered when safely feasible (34); 
better outcomes are reported in patients with single-side 
metastatic disease and longer disease free interval (33); 
although the volume of lung lesion was not statistically 
related to postoperative prognosis, patients requiring a 
major resection—because of centrally located lesions—
presented a poorer prognosis (35); post-chemotherapy 
necrosis <90% in the primary tumor, developing metastases 
during chemotherapy and chondroblastic subtype are 
predictors of poor prognosis (36).
Soft tissue sarcomas are an eterogeneous group of 
mesenchymal cancers (37); they frequently metastasize to 
the lung, despite primary tumor radical resection (38).
Pulmonary metastasectomy is considered the gold 
standard treatment in case of isolated lung metastases, as 
several studies have shown a better survival in patients who 
received metastasectomy (39,40).
According to Giuliano et al., younger age at diagnosis and 
low-grade tumors with longer disease free interval offer the 
greatest survival advantage to radically resected patients (37).
Pediatric cancers
Primary solid cancers of children, such as Ewing’s sarcoma, 
hepatoblastoma, Wilms’ tumor and osteosarcomas, 
commonly metastasize to the lung, having a negative 
prognostic impact (41).
Several reports have shown prolonged survival after 
pulmonary metastasectomy in selected patients presenting 
with isolated lung metastases, mainly in case of osteosarcoma; 
however prognostic factors are still unclear (42,43). The 
5-year survival rates—reported by studies on the role of 
surgery for pulmonary metastases in pediatric patients—
ranged from 20% to 40% (44,45).
Tronc et al. reported that pulmonary metastasectomy is a 
safe and potentially curative treatment in pediatric patients 
presenting secondary lung lesions form solid tumors of 
different histologies. 
The low morbidity rate—as well as the absence 
of mortality—justify an aggressive surgical approach 
combined with chemotherapy; ideal indications for 
lung metastasectomy are a small number of pulmonary 
metastases and a long disease free interval (41).
In a recent report from Stanelle et al., the influence of 
pulmonary metastasectomy for metastatic synovial sarcoma in 
pediatric/adolescent patients has been investigated, disclosing 
that  pulmonary metastasectomy may be associated with 
improved survival if complete resection is achieved (46).
Head and neck cancers
The lungs are the most common target of distant metastases 
form head and neck cancers, including squamous cell 
carcinoma, adenoid-cystic carcinoma and other histologies 
(47,48). These metastatic cancers scarcely respond to 
chemotherapy, and thus surgery has become a valid 
curative alternative if all the general principles of lung 
metastasectomy are respected.
Five-year survival after lung metastasectomy of head and 
neck cancers is reported to range between 50–60% (49); older 
age (≥60 years), short disease free interval (<26 months) and 
histology of squamous cell carcinoma have been reported 
to have an adverse impact on clinical outcome (47,50); 
similarly oral cancers, mediastinal lymph nodes spreading 
and pleural infiltration conditionate a worse prognosis (51).
Patients receiving pulmonary metastasectomy of adenoid 
cystic carcinoma—a slow growing tumor—present an 
estimated 5-year survival rate of 84% (52); on the other 
hand, 5-year survival rate of patients undergoing lung 
resection for squamous cell carcinoma ranges between 
26.5% and 43.0% (53,54).
Lung metastases and primary squamous cell lung 
cancer are difficult to be histopathologically distinguished; 
differential diagnosis is mainly based on clinical aspects (site 
of lung lesion, tumor stage, disease free interval) while, so 
far, genetic analysis does not allow to discriminate between 
metastases of SCC of the head and neck and primary SCC 
lung cancer (51).
Gynecologic cancers 
The incidence of pulmonary metastasis of gynecologic 
cancers ranges between 2.3–4.6% (55) being higher in 
patients suffering from sarcoma or choriocarcinoma than 
in patients affected by epithelial gynecologic cancers like 
cervical, endometrial or ovarian carcinomas (56).
At the moment, The Clinical Practice Guidelines in 
Oncology developed by the National Comprehensive 
Cancer Network (NCCN) suggest surgical resection for 
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removable regional uterine cancer metastasis (55). Several 
studies have shown a 5-year survival rate from 32.9% to 
46.8% (57,58).
Lung metastasectomy—when is a low risk-procedure—
has been shown to ameliorate the long term survival; 
moreover, pulmonary resection, for single lung metastasis 
might offer a better prognosis not only for patients with a 
long relapse free interval but also for patients with tumors 
resistant to chemotherapy or re-recurrent ones (56). 
Patients presenting more than three pulmonary lesions 
and with respiratory symptoms, related to lung metastases, 
could expect to have worse prognosis after lung metastases 
resection (55).
Other malignancies 
Melanoma 
The lungs are the most frequent site of visceral metastases 
from melanoma, comprising 15% to 35% of patients with 
metastatic melanoma (59). Several studies have shown 
improved survival after pulmonary metastasectomy, with 
median survival from 10 to 28 months and 5-year survival 
rates from 4% up to 14–35% (60,61). Positive prognostic 
factors include complete resection, disease-free interval 
greater than 1 year, fewer than three pulmonary nodules, 
absence of extrathoracic and lymph node metastasis, and 
response to chemotherapy/immunotherapy (62,63).
Gastric cancers
The role of lung metastasectomy in gastric cancer patients 
is still unclear (64). As many patients suffering from lung 
metastases form gastric cancers present synchronous 
carcinomatous lymphangitis or pleuritis, pulmonary 
metastasectomy has been rarely reported in this setting, 
thus only few data being available on short and long term 
outcomes (65,66).
Lung metastasectomy for gastric cancer pulmonary 
metastases has been only rarely reported, therefore we 
conclude that pulmonary resection of gastric metastases 
has no evident role in the routinely clinical management 
of metastatic gastric patients and it could be occasionally 
proposed only for highly selected patients (64).
Nonseminomatous germ cell tumors
Nonseminomatous germ cell tumors of testicular origin are 
the most frequent cancers among male patients younger 
than 30 (67); but lungs and the retroperitoneal space are 
commonly the starting site of metastatic spread (68). 
Indications for lung metastasectomy in this cohort 
of patients are: (I) lack of response to chemotherapy; 
(II) only partial response and then recurrence while on 
chemotherapy; (III) recurrence after standard and second 
line treatments; (IV) to check if residual tumor is still 
present; and (V) to resect expanding benign teratomatous 
aspects of the tumor (69). Postoperative 30-day mortality 
rate is reported to range between 0.0 and 0.036 while 5-year 
survival rates range between 73% and 94% (68).
Breast cancers
The lung is a frequent metastatic site for recurrent breast 
cancer but the role of pulmonary resection is still under 
debate, in particular in the light of excellent results of non-
surgical treatments, like hormono or chemotherapy. 
Yhim et al. analyzed clinical outcomes of patients suffering 
from recurrent breast-cancer with less than four pulmonary 
metastases, treated with systemic treatment alone or lung 
resection and then systemic treatment, disclosing that 
pulmonary metastasectomy can be an effective therapeutic 
option for patients with few and small metastases, irrespective 
of poor-prognosis aspects (70). Similarly Planchard et al. 
demonstrated that pulmonary metastasectomy from breast 
carcinoma was associated with a significant 5-year survival 
rate of 45%, but were not able to discriminate whether 
this result was due to the surgical procedure itself or to the 
selection of patients (71); the authors emphasized that when 
resection is evaluated this cohort of patients, both the size of 
the largest metastasis and the disease free interval should be 
carefully considered (71).
Conclusions
Since the establishment of the International Registry of Lung 
Metastases in the 1990s (3), pulmonary metastasectomy has 
been an area of debate between surgeons and oncologists (72). 
However, the lack of controlled trials and studies limited by 
short follow-up and small cohorts did not allow to overcame 
some skepticism; moreover, the heterogeneity of these 
patients in terms of demographic, biologic and histologic 
characteristics represents a clear limit even in the largest 
series (73,74).
On the basis of present knowledge, without results 
coming from on-going randomized trials, radical resection, 
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histology, and disease free interval seem to be independent 
prognostic factors identifying a cohort of patients maximally 
benefitting from lung metastasectomy.
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